ω3-polyunsaturated free fatty acids (ω3-PUFAs), particularly docosahexaenoic (DHA) and eicosapentaenoic acid (EPA), are thought to exert health promoting effects in metabolic and in inflammatory diseases. The molecular mechanisms of these beneficial effects are only partially understood. DHA and EPA activate Free Fatty Acid receptor 4 (GPR120/FFA4). Recently, the first orally available, synthetic ligand of FFA4, 3-[2-chloro-5-(trifluoromethoxy)phenyl]-3-azaspiro[5.5]undecane-9-acetic acid ("compound A"; cpd A) has been developed. Cpd A exhibits distinctly higher potency, efficiency, and selectivity at FFA4 than ω3-PUFAs and ameliorates insulin resistance and adipose tissue inflammation in the mouse. With GPR120/FFA4 activation believed to also attenuate tissue inflammation in autoimmune diseases, cpd A may also have a beneficial effect in these diseases. We have therefore addressed the therapeutic potential of cpd A in mouse models of three prototypical autoimmune diseases, specifically psoriasis, rheumatoid arthritis, and bullous pemphigoid.
| INTRODUCTION
ω3-polyunsaturated free fatty acids (ω3-PUFAs), particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are abundant in fish oil and considered to exert health promoting effects. 1 Thus, high intake of fish oil has been associated with protection from metabolic diseases, such as cardiovascular diseases and type II diabetes, as well as from chronic inflammatory diseases, including psoriasis and rheumatoid arthritis. [1] [2] [3] [4] In line with this, the increase in the incidence of chronic inflammatory diseases in Western societies coincided with a shift in ω3-and ω6-PUFA intake from a ratio ω6-to ω3-PUFAs of 1:1 to approximately 15:1.
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These associations have prompted numerous clinical trials investigating the therapeutic potential of fish oil or purified esters of DHA and EPA in different medical conditions. Among chronic inflammatory diseases, their effect has most frequently been studied in psoriasis and in rheumatoid arthritis. The setup of these trials was quite heterogeneous in respect to the ω3-PUFAs preparations, doses, and routes of administration used as well as in respect to the features of the patient cohorts and the clinical parameters used to benchmark therapeutic effects. The results of these trials have recently been exhaustively summarized and analyzed in two systematic reviews. 4, 5 Collectively, most trials investigating the effect in rheumatoid arthritis demonstrated moderate, beneficial effects. 5 The results on the therapeutic effects of ω3-PUFAs on psoriasis have been more contradictory with some trials reporting beneficial effects, others finding no effect. 4 The potential reasons for these conflicting results are manifold. An obvious explanation is that the therapeutic potential of ω3-PUFAs is too moderate, thus, eliciting either no or only little suppression of disease activity in clinical trials including only small numbers of patients. Further, ω3-PUFAs may be only effective in certain patient subgroups of the respective diseases. This situation precipitates the idea that compounds metabolically more stable than ω3-PUFAs and pharmacologically engaging the pathways downstream of ω3-PUFAs more potently than ω3-PUFAs themselves may be therapeutically more effective.
Mechanistically, the health-promoting effects of ω3-PUFAs are thought to be implemented by multiple and diverse modes of action, including the conversion of ω3-PUFAs to proresolving lipid mediators and PPARγ agonists, substrate competition with arachidonic acid, thus, inhibiting the biosynthesis of proinflammatory eicosanoids, including that of leukotriene B 4 (LTB 4 ), as well as changes in the biophysical properties of cell membranes. 2, 6 This concept of the molecular mode of action of ω3-PUFAs has been extended by another putatively most important mechanism since DHA and EPA were identified as cognate ligands of the G protein-coupled receptor (GPCR) 120. GPR120 was deorph- Pharmacology. 9 Recently, the group of natural GPR120/FFA4 agonists has been extended by a class of newly discovered lipid mediators: the branched fatty acid esters of hydroxy fatty acids (FAHFAs) with the FAHFAs palmitic-acid-9-hydroxy-stearic-acid (9-PAHSA) and palmitic-acid-5-hydroxy-stearic-acid (5-PAHSA) activate FFA4. 10 In contrast to ω3-PUFAs, mammals biosynthesize
PAHSAs. Thus, their identification as GPR120/FFA4 ligands marks the discovery of endogenous ligands of FFA4, whose abundance is independent of nutritional intake.
GPR120/FFA4 is widely expressed and is present on parenchymal and epithelial cells of the gut, liver, adipose tissue, pancreas, and taste buds. To date, most extensively investigated physiological role of GPR120/FFA4 is its positive effect on insulin sensitivity, which has sparked broad interest into the development of GPR120/FFA4
agonists as novel antidiabetics. 11 In recent years, it has been shown that FFA4 is also expressed on immune cells, including monocytes/ macrophages, dendritic cells, and eosinophils, 8, 10, 12 suggesting that GPR120/FFA4 may mediate immunomodulatory actions of ω3-PUFAs. In line with this notion, in vitro activation of GPR120/FFA4
in macrophages curbs their immune response to NLPR3 inflammasome, TLR4, or TNF-α activation, [13] [14] [15] and in vivo GPR120 is [17] [18] [19] In this study, we have addressed the therapeutic potential of cpd A in mouse models of these three common, prototypical, autoimmune diseases using the Aldar ™ -induced psoriasis-like dermatitis model, the K/BxN serum transfer model, and the antibody transfer bullous pemphigoid-like epidermolysis bullosa acquisita mouse model, respectively. [20] [21] [22] In all three models, cpd A did not exhibit therapeutic efficiency, indicating that the antiinflammatory effects, induced by GPR120/FFA4 activation, do not reach the level to ameliorate clinically symptomatic tissue inflammation. Our results therefore discourage the use of GPR120/FFA4 agonists in monotherapeutic regimens in the treatment of inflammatory diseases.
| MATERIALS AND METHODS

| Mice
C57BL/6J wild-type were purchased from JANVIER LABS (SaintBerthevin Cedex, France). They were housed in a 12-hour light-dark cycle in the animal facility of the University of Lübeck (Lübeck, Germany) and fed with standard chow diet. All experiments were performed in 8-to 12-week-old age-and sex-matched mice by certified personnel. All experiments had been permitted by the state government of Schleswig-Holstein.
| Preparation and administration of the FF4/ GPR120 agonist compound A
The FFA4/GPR120 agonist 3-[2-chloro-5-(trifluoromethoxy)phenyl]-3-azaspiro[5.5]undecane-9-acetic acid (compound A; cpd A), previously described, 16 was purchased from Biomol GmbH (Hamburg, Germany). Cpd A was solved in 10% DMSO in PBS. In all experiments, 50 mg/kg body weight cpd A was administered by oral gavage daily.
In the control group, the mice instead received only the vehicle, 10% DMSO in PBS. Both, cpd A and its vehicle control were well tolerated throughout the experiments. In all three mouse models used in this study, cpd A treatment was started 2 days before the first induction of disease (day −2). This pretreatment regimen was chosen to facilitate detecting possible beneficial effects of cpd A with administration regimens aiming at suppressing emerging tissue inflammation often exhibiting more pronounced effects than therapeutic regimens aiming at reversing established tissue inflammation.
| Induction and clinical evaluation of psoriasislike dermatitis
To induce psoriasis-like dermatitis, the Aldara ™ -induced psoriasis-like dermatitis (AIPD) mouse model, in literature often also referred to as "imiquimod-induced psoriasis-like dermatitis mouse model" was conducted, as previously described. 23, 24 Briefly, a 2 × 3 cm large area was depilated on the back 2 days before the first application of Aldara ™ cream (Meda, Solnau, Sweden). Starting from day 0, 50 mg Aldara ™ cream was daily applied on the back, and 5 mg on the dorsal surface of the ears for five consecutive days. On the back, the severity of psoriasis-like dermatitis was determined using the Psoriasis Activity and Severity Index (PASI). Thus, erythema, infiltration, and desquamation were individually scored on a scale from 0 to 4 with 0, none; 1, mild; 2, moderate; 3, marked; 4; severe. Finally, the scores of these individual aspects of dermatitis were summed up to calculate the cumulative disease score. At the ear, the severity of psoriasis-like dermatitis was assessed by measuring the dorsal-ventral distance of the ear daily before the application of Aldara ™ cream using a micrometer (Mitutoyo Europe, Neuss, Germany) and subsequently calculating ear swelling, i.e., the change of the dorsal-ventral distance compared to day 0.
| Induction and evaluation of arthritis
To induce arthritis, the K/BxN serum transfer model of rheumatoid arthritis was used, as previously described. 
| Induction and clinical scoring of pemphigoid disease-like dermatitis
To generate pemphigoid disease-like dermatitis in mice, the antibody transfer bullous pemphigoid-like epidermolysis bullosa acquisita (BP-like EBA) mouse model was performed, as previously described. 27 Thus, in a first step, to generate IgG antibodies directed to type VII collagen (anti-Col7 IgG), rabbits were immunized against three epitopes of type VII collagen, and IgG directed to the epitope C (anti-Col7c IgG) was subsequently isolated from rabbit serum, as previously described. 21 Purified anti-Col7c IgG was filter-sterilized (pore size: 0.2 μm), and its concentration was and, subsequently, the percentage of the total body surface affected by skin lesions (ABSA) was calculated. 
| Histopathology of the skin
| Statistical analysis
All data are presented as mean ± SEM. Results were tested for statistical differences using GraphPad Prism 7.0 (GraphPad, San Diego, CA, USA). P < 0.05 was considered statistically significant. Clinical scores were compared by two-way ANOVA with Sidak's multiple 3 | RESULTS
| CpdA does not modulate the course of psoriasis-like dermatitis
To evaluate the potential of cpd A as therapeutic in psoriasis, we induced psoriasis-like skin inflammation in C57Bl/6 wild-type mice, as described in Methods, and treated one group of mice daily with cpd A by gavage starting 2 days before the first application of Aldara Figure 2D ). There were no detectable differences between the two groups.
| Cpd A does not alter the course of pemphigoid disease-like dermatitis
We applied the antibody transfer BP-like EBA mouse model as a third prototypical example for a chronic inflammatory disease to 
| DISCUSSION
High intake of ω3-PUFAs is associated with protection from a wide spectrum of inflammatory diseases, including rheumatoid arthritis and psoriasis. Accordingly, the therapeutic potential of ω3-PUFAs has been evaluated in several clinical studies, which, in sum, suggest that the therapeutic administration of ω3-PUFAs, if at all, only exerts moderate therapeutic effects. 4, 30 Thus, to exploit the molecular mechanisms, applied by ω3-PUFAs, small molecules, which more potently activate these mechanisms and are pharmacologically better controllable and predictable in their effects than ω3-PUFAs, are required. In pursuit of this goal, we have scrutinized here the therapeutic potential of the first orally available GPR120/FFA4 agonist, cpd A, in three mouse models of prototypic inflammatory diseases.
Although cpd A is in its agonistic, pharmacological properties toward GPR120/FFA4 far superior to ω3-PUFAs, 16 it did not modulate the severity of disease in any of the three mouse models, Notably, the in vivo significance of GPR120/FFA4 to suppress chronic low-grade inflammation also has lately been contended. While GPR120/FFA4 activation by ω3-PUFAs was initially reported to be critical to reduce high-fat diet-induced adipose tissue inflammation, 14 more recent studies found GPR120/FFA4 to be dispensable for the therapeutic effects of ω3-PUFAs in mouse models of both high-fat diet-induced adipose tissue inflammation, and of atherosclerosis. 35, 36 The reason for these discrepant findings is unknown and numerous explanations are conceivable. Inflammation is a most complex process and ω3-PUFAs can exert diverse pharmacological actions independent of GPR120/FFA4. It would not be surprising if the relative contribution of GPR120 to regulate tissue inflammation varies depending on the detailed conditions of the organism. The conditions under which GPR120/FFA4 activation elicits antiinflammatory effects in vivo therefore must be exactly defined.
In conclusion, our results suggest that targeting GPR120/FFA4 alone is not a promising concept for the development of new treatments for diseases featuring acute tissue inflammation. Future studies should, therefore rather, address whether small molecules individually engaging other molecular mechanisms contributing to the putative beneficial effects of ω3-PUFAs, such as the receptors for proresolving lipid mediators, are more effective than GPR120/ FFA4 engagement in ameliorating tissue inflammation. Alternatively, multipronged therapeutic strategies, in parallel engaging several of these molecular mechanisms to elicit relevant therapeutic effects, may be examined.
